2019 IPO
NGM Biopharmaceuticals Stock
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Sign up today and learn more about NGM Biopharmaceuticals Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About NGM Biopharmaceuticals Stock
NGM Biopharmaceuticals, Inc. is a privately held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. Our current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
Funding History
| December 2009 | $26.6M |
|---|---|
| November 2011 | $55.4M |
| July 2013 | $50.0M |
| March 2015 | $106M |
| March 2015 | $57.5M |
Management
Vice President, Research
Hui Tian
Vice President, Business Development
Aetna Wun Trombley
Vice President, Clinical Research
Alex DePaoli
Chief Executive Officer
David Woodhouse
Executive Director, Research Operations
Marc Learned
CEO
William J. Rieflin
Vice President CMC and Technical Operations
Chuck Olson
Senior Director, Protein Sciences
Thomas Parsons
CFO
Luis Bayol
Founder, President and Chief Scientific Officer
Jin-Long Chen
Press
TechCrunch - Jul, 8 2017
These South Bay and Peninsula cities are raking in venture capitalEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
